Spectroscopy in Diagnosing Dysplasia and Neoplasia in the Cervix in Women Undergoing Colposcopy
Launched by BRITISH COLUMBIA CANCER AGENCY · Mar 7, 2008
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES:
* To identify potential improvements for a noninvasive method of diagnosing dysplasia and neoplasia in the cervix using fluorescence and reflectance spectroscopy.
* To measure the reflection and fluorescence spectra in vivo of sites in the human cervix.
* To further refine fluorescence spectroscopy for detection of cervical lesions via better classification of normal columnar tissue and non-neoplastic tissue with inflammation, and low- and high-grade squamous intraepithelial lesions.
* Evaluate and validate the wavelength selections for the spectroscopy device derived from in v...
Gender
FEMALE
Eligibility criteria
- DISEASE CHARACTERISTICS:
- • Referred to the Colposcopy clinic at Vancouver General Hospital, the MD Anderson Cancer Center, or the University of Texas at Austin
- • Abnormal or normal Papanicolaou smear
- • Hormone receptor status not specified
- PATIENT CHARACTERISTICS:
- • Pre or post-menopausal
- • Not pregnant
- PRIOR CONCURRENT THERAPY:
- • Not specified
About British Columbia Cancer Agency
The British Columbia Cancer Agency (BCCA) is a leading organization dedicated to cancer research, treatment, and prevention in Canada. As a prominent clinical trial sponsor, BCCA focuses on advancing cancer care through innovative research and the development of new therapeutic strategies. With a commitment to improving patient outcomes, BCCA collaborates with a network of healthcare professionals and research institutions to conduct rigorous clinical trials that explore cutting-edge treatments and diagnostic methods. Their multidisciplinary approach, combined with a strong emphasis on patient-centered care, positions BCCA at the forefront of cancer research and healthcare advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Sylvia Lam
British Columbia Cancer Agency
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials